Home Healthcare Biotechnology Antisense and RNAi Therapeutics Market

Antisense and RNAi Therapeutics Market Size, Share & Trends Analysis Report By Technology (RNA Interference, siRNA, miRNA, Antisense RNA), By Application (Oncology, Cardiovascular Diseases (CVDs), Respiratory Disorders, Renal Diseases, Neurodegenerative Disorders, Genetic Disorders, Infectious Diseases, Others), By Route of Administration (Intravenous Route, Subcutaneous Route, Intrathecal Route, Pulmonary Delivery, Intraperitoneal Injection, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: May 25, 2026 | Author: Mitiksha Koul | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Antisense and RNAi Therapeutics Market, By Technology 2022-2034 (USD MILLION/ Units)
    1. RNA Interference
    2. siRNA
    3. miRNA
    4. Antisense RNA
  2. Antisense and RNAi Therapeutics Market, By Application 2022-2034 (USD MILLION/ Units)
    1. Oncology
    2. Cardiovascular Diseases (CVDs)
    3. Respiratory Disorders
    4. Renal Diseases
    5. Neurodegenerative Disorders
    6. Genetic Disorders
    7. Infectious Diseases
    8. Others
  3. Antisense and RNAi Therapeutics Market, By Route of Administration 2022-2034 (USD MILLION/ Units)
    1. Intravenous Route
    2. Subcutaneous Route
    3. Intrathecal Route
    4. Pulmonary Delivery
    5. Intraperitoneal Injection
    6. Others
  4. Regional Antisense and RNAi Therapeutics Market
    1. North America
      1. North America Antisense and RNAi Therapeutics Market By Technology 2022-2034 (USD MILLION/ Units)
        1. RNA Interference
        2. siRNA
        3. miRNA
        4. Antisense RNA
      2. North America Antisense and RNAi Therapeutics Market By Application 2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Cardiovascular Diseases (CVDs)
        3. Respiratory Disorders
        4. Renal Diseases
        5. Neurodegenerative Disorders
        6. Genetic Disorders
        7. Infectious Diseases
        8. Others
      3. North America Antisense and RNAi Therapeutics Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Intravenous Route
        2. Subcutaneous Route
        3. Intrathecal Route
        4. Pulmonary Delivery
        5. Intraperitoneal Injection
        6. Others
      4. U.S.
        1. RNA Interference
        2. siRNA
        3. miRNA
        4. Antisense RNA
        5. Oncology
        6. Cardiovascular Diseases (CVDs)
        7. Respiratory Disorders
        8. Renal Diseases
        9. Neurodegenerative Disorders
        10. Genetic Disorders
        11. Infectious Diseases
        12. Others
        13. Intravenous Route
        14. Subcutaneous Route
        15. Intrathecal Route
        16. Pulmonary Delivery
        17. Intraperitoneal Injection
        18. Others
      5. Canada
        1. RNA Interference
        2. siRNA
        3. miRNA
        4. Antisense RNA
        5. Oncology
        6. Cardiovascular Diseases (CVDs)
        7. Respiratory Disorders
        8. Renal Diseases
        9. Neurodegenerative Disorders
        10. Genetic Disorders
        11. Infectious Diseases
        12. Others
        13. Intravenous Route
        14. Subcutaneous Route
        15. Intrathecal Route
        16. Pulmonary Delivery
        17. Intraperitoneal Injection
        18. Others
    2. Europe
      1. Europe Antisense and RNAi Therapeutics Market By Technology 2022-2034 (USD MILLION/ Units)
        1. RNA Interference
        2. siRNA
        3. miRNA
        4. Antisense RNA
      2. Europe Antisense and RNAi Therapeutics Market By Application 2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Cardiovascular Diseases (CVDs)
        3. Respiratory Disorders
        4. Renal Diseases
        5. Neurodegenerative Disorders
        6. Genetic Disorders
        7. Infectious Diseases
        8. Others
      3. Europe Antisense and RNAi Therapeutics Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Intravenous Route
        2. Subcutaneous Route
        3. Intrathecal Route
        4. Pulmonary Delivery
        5. Intraperitoneal Injection
        6. Others
      4. U.K.
        1. RNA Interference
        2. siRNA
        3. miRNA
        4. Antisense RNA
        5. Oncology
        6. Cardiovascular Diseases (CVDs)
        7. Respiratory Disorders
        8. Renal Diseases
        9. Neurodegenerative Disorders
        10. Genetic Disorders
        11. Infectious Diseases
        12. Others
        13. Intravenous Route
        14. Subcutaneous Route
        15. Intrathecal Route
        16. Pulmonary Delivery
        17. Intraperitoneal Injection
        18. Others
      5. Germany
        1. RNA Interference
        2. siRNA
        3. miRNA
        4. Antisense RNA
        5. Oncology
        6. Cardiovascular Diseases (CVDs)
        7. Respiratory Disorders
        8. Renal Diseases
        9. Neurodegenerative Disorders
        10. Genetic Disorders
        11. Infectious Diseases
        12. Others
        13. Intravenous Route
        14. Subcutaneous Route
        15. Intrathecal Route
        16. Pulmonary Delivery
        17. Intraperitoneal Injection
        18. Others
      6. France
        1. RNA Interference
        2. siRNA
        3. miRNA
        4. Antisense RNA
        5. Oncology
        6. Cardiovascular Diseases (CVDs)
        7. Respiratory Disorders
        8. Renal Diseases
        9. Neurodegenerative Disorders
        10. Genetic Disorders
        11. Infectious Diseases
        12. Others
        13. Intravenous Route
        14. Subcutaneous Route
        15. Intrathecal Route
        16. Pulmonary Delivery
        17. Intraperitoneal Injection
        18. Others
      7. Spain
        1. RNA Interference
        2. siRNA
        3. miRNA
        4. Antisense RNA
        5. Oncology
        6. Cardiovascular Diseases (CVDs)
        7. Respiratory Disorders
        8. Renal Diseases
        9. Neurodegenerative Disorders
        10. Genetic Disorders
        11. Infectious Diseases
        12. Others
        13. Intravenous Route
        14. Subcutaneous Route
        15. Intrathecal Route
        16. Pulmonary Delivery
        17. Intraperitoneal Injection
        18. Others
      8. Italy
        1. RNA Interference
        2. siRNA
        3. miRNA
        4. Antisense RNA
        5. Oncology
        6. Cardiovascular Diseases (CVDs)
        7. Respiratory Disorders
        8. Renal Diseases
        9. Neurodegenerative Disorders
        10. Genetic Disorders
        11. Infectious Diseases
        12. Others
        13. Intravenous Route
        14. Subcutaneous Route
        15. Intrathecal Route
        16. Pulmonary Delivery
        17. Intraperitoneal Injection
        18. Others
      9. Russia
        1. RNA Interference
        2. siRNA
        3. miRNA
        4. Antisense RNA
        5. Oncology
        6. Cardiovascular Diseases (CVDs)
        7. Respiratory Disorders
        8. Renal Diseases
        9. Neurodegenerative Disorders
        10. Genetic Disorders
        11. Infectious Diseases
        12. Others
        13. Intravenous Route
        14. Subcutaneous Route
        15. Intrathecal Route
        16. Pulmonary Delivery
        17. Intraperitoneal Injection
        18. Others
      10. Nordic
        1. RNA Interference
        2. siRNA
        3. miRNA
        4. Antisense RNA
        5. Oncology
        6. Cardiovascular Diseases (CVDs)
        7. Respiratory Disorders
        8. Renal Diseases
        9. Neurodegenerative Disorders
        10. Genetic Disorders
        11. Infectious Diseases
        12. Others
        13. Intravenous Route
        14. Subcutaneous Route
        15. Intrathecal Route
        16. Pulmonary Delivery
        17. Intraperitoneal Injection
        18. Others
      11. Benelux
        1. RNA Interference
        2. siRNA
        3. miRNA
        4. Antisense RNA
        5. Oncology
        6. Cardiovascular Diseases (CVDs)
        7. Respiratory Disorders
        8. Renal Diseases
        9. Neurodegenerative Disorders
        10. Genetic Disorders
        11. Infectious Diseases
        12. Others
        13. Intravenous Route
        14. Subcutaneous Route
        15. Intrathecal Route
        16. Pulmonary Delivery
        17. Intraperitoneal Injection
        18. Others
      12. Rest of Europe
        1. RNA Interference
        2. siRNA
        3. miRNA
        4. Antisense RNA
        5. Oncology
        6. Cardiovascular Diseases (CVDs)
        7. Respiratory Disorders
        8. Renal Diseases
        9. Neurodegenerative Disorders
        10. Genetic Disorders
        11. Infectious Diseases
        12. Others
        13. Intravenous Route
        14. Subcutaneous Route
        15. Intrathecal Route
        16. Pulmonary Delivery
        17. Intraperitoneal Injection
        18. Others
    3. APAC
      1. APAC Antisense and RNAi Therapeutics Market By Technology 2022-2034 (USD MILLION/ Units)
        1. RNA Interference
        2. siRNA
        3. miRNA
        4. Antisense RNA
      2. APAC Antisense and RNAi Therapeutics Market By Application 2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Cardiovascular Diseases (CVDs)
        3. Respiratory Disorders
        4. Renal Diseases
        5. Neurodegenerative Disorders
        6. Genetic Disorders
        7. Infectious Diseases
        8. Others
      3. APAC Antisense and RNAi Therapeutics Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Intravenous Route
        2. Subcutaneous Route
        3. Intrathecal Route
        4. Pulmonary Delivery
        5. Intraperitoneal Injection
        6. Others
      4. China
        1. RNA Interference
        2. siRNA
        3. miRNA
        4. Antisense RNA
        5. Oncology
        6. Cardiovascular Diseases (CVDs)
        7. Respiratory Disorders
        8. Renal Diseases
        9. Neurodegenerative Disorders
        10. Genetic Disorders
        11. Infectious Diseases
        12. Others
        13. Intravenous Route
        14. Subcutaneous Route
        15. Intrathecal Route
        16. Pulmonary Delivery
        17. Intraperitoneal Injection
        18. Others
      5. Korea
        1. RNA Interference
        2. siRNA
        3. miRNA
        4. Antisense RNA
        5. Oncology
        6. Cardiovascular Diseases (CVDs)
        7. Respiratory Disorders
        8. Renal Diseases
        9. Neurodegenerative Disorders
        10. Genetic Disorders
        11. Infectious Diseases
        12. Others
        13. Intravenous Route
        14. Subcutaneous Route
        15. Intrathecal Route
        16. Pulmonary Delivery
        17. Intraperitoneal Injection
        18. Others
      6. Japan
        1. RNA Interference
        2. siRNA
        3. miRNA
        4. Antisense RNA
        5. Oncology
        6. Cardiovascular Diseases (CVDs)
        7. Respiratory Disorders
        8. Renal Diseases
        9. Neurodegenerative Disorders
        10. Genetic Disorders
        11. Infectious Diseases
        12. Others
        13. Intravenous Route
        14. Subcutaneous Route
        15. Intrathecal Route
        16. Pulmonary Delivery
        17. Intraperitoneal Injection
        18. Others
      7. India
        1. RNA Interference
        2. siRNA
        3. miRNA
        4. Antisense RNA
        5. Oncology
        6. Cardiovascular Diseases (CVDs)
        7. Respiratory Disorders
        8. Renal Diseases
        9. Neurodegenerative Disorders
        10. Genetic Disorders
        11. Infectious Diseases
        12. Others
        13. Intravenous Route
        14. Subcutaneous Route
        15. Intrathecal Route
        16. Pulmonary Delivery
        17. Intraperitoneal Injection
        18. Others
      8. Australia
        1. RNA Interference
        2. siRNA
        3. miRNA
        4. Antisense RNA
        5. Oncology
        6. Cardiovascular Diseases (CVDs)
        7. Respiratory Disorders
        8. Renal Diseases
        9. Neurodegenerative Disorders
        10. Genetic Disorders
        11. Infectious Diseases
        12. Others
        13. Intravenous Route
        14. Subcutaneous Route
        15. Intrathecal Route
        16. Pulmonary Delivery
        17. Intraperitoneal Injection
        18. Others
      9. Singapore
        1. RNA Interference
        2. siRNA
        3. miRNA
        4. Antisense RNA
        5. Oncology
        6. Cardiovascular Diseases (CVDs)
        7. Respiratory Disorders
        8. Renal Diseases
        9. Neurodegenerative Disorders
        10. Genetic Disorders
        11. Infectious Diseases
        12. Others
        13. Intravenous Route
        14. Subcutaneous Route
        15. Intrathecal Route
        16. Pulmonary Delivery
        17. Intraperitoneal Injection
        18. Others
      10. Taiwan
        1. RNA Interference
        2. siRNA
        3. miRNA
        4. Antisense RNA
        5. Oncology
        6. Cardiovascular Diseases (CVDs)
        7. Respiratory Disorders
        8. Renal Diseases
        9. Neurodegenerative Disorders
        10. Genetic Disorders
        11. Infectious Diseases
        12. Others
        13. Intravenous Route
        14. Subcutaneous Route
        15. Intrathecal Route
        16. Pulmonary Delivery
        17. Intraperitoneal Injection
        18. Others
      11. South East Asia
        1. RNA Interference
        2. siRNA
        3. miRNA
        4. Antisense RNA
        5. Oncology
        6. Cardiovascular Diseases (CVDs)
        7. Respiratory Disorders
        8. Renal Diseases
        9. Neurodegenerative Disorders
        10. Genetic Disorders
        11. Infectious Diseases
        12. Others
        13. Intravenous Route
        14. Subcutaneous Route
        15. Intrathecal Route
        16. Pulmonary Delivery
        17. Intraperitoneal Injection
        18. Others
      12. Rest of Asia-Pacific
        1. RNA Interference
        2. siRNA
        3. miRNA
        4. Antisense RNA
        5. Oncology
        6. Cardiovascular Diseases (CVDs)
        7. Respiratory Disorders
        8. Renal Diseases
        9. Neurodegenerative Disorders
        10. Genetic Disorders
        11. Infectious Diseases
        12. Others
        13. Intravenous Route
        14. Subcutaneous Route
        15. Intrathecal Route
        16. Pulmonary Delivery
        17. Intraperitoneal Injection
        18. Others
    4. Middle East and Africa
      1. Middle East and Africa Antisense and RNAi Therapeutics Market By Technology 2022-2034 (USD MILLION/ Units)
        1. RNA Interference
        2. siRNA
        3. miRNA
        4. Antisense RNA
      2. Middle East and Africa Antisense and RNAi Therapeutics Market By Application 2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Cardiovascular Diseases (CVDs)
        3. Respiratory Disorders
        4. Renal Diseases
        5. Neurodegenerative Disorders
        6. Genetic Disorders
        7. Infectious Diseases
        8. Others
      3. Middle East and Africa Antisense and RNAi Therapeutics Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Intravenous Route
        2. Subcutaneous Route
        3. Intrathecal Route
        4. Pulmonary Delivery
        5. Intraperitoneal Injection
        6. Others
      4. UAE
        1. RNA Interference
        2. siRNA
        3. miRNA
        4. Antisense RNA
        5. Oncology
        6. Cardiovascular Diseases (CVDs)
        7. Respiratory Disorders
        8. Renal Diseases
        9. Neurodegenerative Disorders
        10. Genetic Disorders
        11. Infectious Diseases
        12. Others
        13. Intravenous Route
        14. Subcutaneous Route
        15. Intrathecal Route
        16. Pulmonary Delivery
        17. Intraperitoneal Injection
        18. Others
      5. Turkey
        1. RNA Interference
        2. siRNA
        3. miRNA
        4. Antisense RNA
        5. Oncology
        6. Cardiovascular Diseases (CVDs)
        7. Respiratory Disorders
        8. Renal Diseases
        9. Neurodegenerative Disorders
        10. Genetic Disorders
        11. Infectious Diseases
        12. Others
        13. Intravenous Route
        14. Subcutaneous Route
        15. Intrathecal Route
        16. Pulmonary Delivery
        17. Intraperitoneal Injection
        18. Others
      6. Saudi Arabia
        1. RNA Interference
        2. siRNA
        3. miRNA
        4. Antisense RNA
        5. Oncology
        6. Cardiovascular Diseases (CVDs)
        7. Respiratory Disorders
        8. Renal Diseases
        9. Neurodegenerative Disorders
        10. Genetic Disorders
        11. Infectious Diseases
        12. Others
        13. Intravenous Route
        14. Subcutaneous Route
        15. Intrathecal Route
        16. Pulmonary Delivery
        17. Intraperitoneal Injection
        18. Others
      7. South Africa
        1. RNA Interference
        2. siRNA
        3. miRNA
        4. Antisense RNA
        5. Oncology
        6. Cardiovascular Diseases (CVDs)
        7. Respiratory Disorders
        8. Renal Diseases
        9. Neurodegenerative Disorders
        10. Genetic Disorders
        11. Infectious Diseases
        12. Others
        13. Intravenous Route
        14. Subcutaneous Route
        15. Intrathecal Route
        16. Pulmonary Delivery
        17. Intraperitoneal Injection
        18. Others
      8. Egypt
        1. RNA Interference
        2. siRNA
        3. miRNA
        4. Antisense RNA
        5. Oncology
        6. Cardiovascular Diseases (CVDs)
        7. Respiratory Disorders
        8. Renal Diseases
        9. Neurodegenerative Disorders
        10. Genetic Disorders
        11. Infectious Diseases
        12. Others
        13. Intravenous Route
        14. Subcutaneous Route
        15. Intrathecal Route
        16. Pulmonary Delivery
        17. Intraperitoneal Injection
        18. Others
      9. Nigeria
        1. RNA Interference
        2. siRNA
        3. miRNA
        4. Antisense RNA
        5. Oncology
        6. Cardiovascular Diseases (CVDs)
        7. Respiratory Disorders
        8. Renal Diseases
        9. Neurodegenerative Disorders
        10. Genetic Disorders
        11. Infectious Diseases
        12. Others
        13. Intravenous Route
        14. Subcutaneous Route
        15. Intrathecal Route
        16. Pulmonary Delivery
        17. Intraperitoneal Injection
        18. Others
      10. Rest of MEA
        1. RNA Interference
        2. siRNA
        3. miRNA
        4. Antisense RNA
        5. Oncology
        6. Cardiovascular Diseases (CVDs)
        7. Respiratory Disorders
        8. Renal Diseases
        9. Neurodegenerative Disorders
        10. Genetic Disorders
        11. Infectious Diseases
        12. Others
        13. Intravenous Route
        14. Subcutaneous Route
        15. Intrathecal Route
        16. Pulmonary Delivery
        17. Intraperitoneal Injection
        18. Others
    5. LATAM
      1. LATAM Antisense and RNAi Therapeutics Market By Technology 2022-2034 (USD MILLION/ Units)
        1. RNA Interference
        2. siRNA
        3. miRNA
        4. Antisense RNA
      2. LATAM Antisense and RNAi Therapeutics Market By Application 2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Cardiovascular Diseases (CVDs)
        3. Respiratory Disorders
        4. Renal Diseases
        5. Neurodegenerative Disorders
        6. Genetic Disorders
        7. Infectious Diseases
        8. Others
      3. LATAM Antisense and RNAi Therapeutics Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Intravenous Route
        2. Subcutaneous Route
        3. Intrathecal Route
        4. Pulmonary Delivery
        5. Intraperitoneal Injection
        6. Others
      4. Brazil
        1. RNA Interference
        2. siRNA
        3. miRNA
        4. Antisense RNA
        5. Oncology
        6. Cardiovascular Diseases (CVDs)
        7. Respiratory Disorders
        8. Renal Diseases
        9. Neurodegenerative Disorders
        10. Genetic Disorders
        11. Infectious Diseases
        12. Others
        13. Intravenous Route
        14. Subcutaneous Route
        15. Intrathecal Route
        16. Pulmonary Delivery
        17. Intraperitoneal Injection
        18. Others
      5. Mexico
        1. RNA Interference
        2. siRNA
        3. miRNA
        4. Antisense RNA
        5. Oncology
        6. Cardiovascular Diseases (CVDs)
        7. Respiratory Disorders
        8. Renal Diseases
        9. Neurodegenerative Disorders
        10. Genetic Disorders
        11. Infectious Diseases
        12. Others
        13. Intravenous Route
        14. Subcutaneous Route
        15. Intrathecal Route
        16. Pulmonary Delivery
        17. Intraperitoneal Injection
        18. Others
      6. Argentina
        1. RNA Interference
        2. siRNA
        3. miRNA
        4. Antisense RNA
        5. Oncology
        6. Cardiovascular Diseases (CVDs)
        7. Respiratory Disorders
        8. Renal Diseases
        9. Neurodegenerative Disorders
        10. Genetic Disorders
        11. Infectious Diseases
        12. Others
        13. Intravenous Route
        14. Subcutaneous Route
        15. Intrathecal Route
        16. Pulmonary Delivery
        17. Intraperitoneal Injection
        18. Others
      7. Chile
        1. RNA Interference
        2. siRNA
        3. miRNA
        4. Antisense RNA
        5. Oncology
        6. Cardiovascular Diseases (CVDs)
        7. Respiratory Disorders
        8. Renal Diseases
        9. Neurodegenerative Disorders
        10. Genetic Disorders
        11. Infectious Diseases
        12. Others
        13. Intravenous Route
        14. Subcutaneous Route
        15. Intrathecal Route
        16. Pulmonary Delivery
        17. Intraperitoneal Injection
        18. Others
      8. Colombia
        1. RNA Interference
        2. siRNA
        3. miRNA
        4. Antisense RNA
        5. Oncology
        6. Cardiovascular Diseases (CVDs)
        7. Respiratory Disorders
        8. Renal Diseases
        9. Neurodegenerative Disorders
        10. Genetic Disorders
        11. Infectious Diseases
        12. Others
        13. Intravenous Route
        14. Subcutaneous Route
        15. Intrathecal Route
        16. Pulmonary Delivery
        17. Intraperitoneal Injection
        18. Others
      9. Rest of LATAM
        1. RNA Interference
        2. siRNA
        3. miRNA
        4. Antisense RNA
        5. Oncology
        6. Cardiovascular Diseases (CVDs)
        7. Respiratory Disorders
        8. Renal Diseases
        9. Neurodegenerative Disorders
        10. Genetic Disorders
        11. Infectious Diseases
        12. Others
        13. Intravenous Route
        14. Subcutaneous Route
        15. Intrathecal Route
        16. Pulmonary Delivery
        17. Intraperitoneal Injection
        18. Others
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.